Get the Stockscreener App
358.33
1.56%
5.51
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $358.33, with a volume of 3.57M.
It is up +1.56% in the last 24 hours and up +6.66% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$352.82
Open:
$354.69
24h Volume:
3.57M
Relative Volume:
1.32
Market Cap:
$193.39B
Revenue:
$37.30B
Net Income/Loss:
$7.80B
P/E Ratio:
24.92
EPS:
14.3793
Net Cash Flow:
$8.60B
1W Performance:
+6.14%
1M Performance:
+6.66%
6M Performance:
+7.63%
1Y Performance:
+28.38%
1-Day Range:
$354.16
$362.27
1-Week Range:
$337.60
$362.27
52-Week Range:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
358.33 | 193.39B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,208.12 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
254.66 | 613.02B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
253.35 | 447.62B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
128.66 | 317.77B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.41 | 296.54B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Hold |
| Mar-10-26 | Initiated | Jefferies | Hold |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Jan-20-26 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-05-25 | Upgrade | Erste Group | Hold → Buy |
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
Amgen Sunday strategy focus, stock and pipeline under long-term scrutiny - Ad-hoc-news.de
Janney Montgomery Scott LLC Decreases Stake in Amgen Inc. $AMGN - MarketBeat
Nicholas Wealth LLC. Takes $1.16 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Nearly 1 million bottles of heart and kidney medication recalled over foreign substance found on tablets - Fox Business
Price to book forward of Amgen Inc. – NASDAQ:AMGN - TradingView
The Evenity from Amgen Inc.osteoporosis therapy with a defined 12-month window - Ad-hoc-news.de
Amgen updates phase 2 obesity data, shares closely watched by health investors - Ad-hoc-news.de
Amgen (AMGN) Faces EU Withdrawal Risk for Tavneos Due to Data In - GuruFocus
900,000 Bottles of Heart and Kidney Medications Recalled For 'Unexpected Foreign Matter' in Bottles - People.com
Nearly 1 million bottles of medication used to treat heart failure recalled nationwide - PIX11
EMA: Amgen, Vifor Inflammatory Drug’s Benefits No Longer Outweigh Risks - MedCity News
What Does Rep. Salazar's Amgen Purchase Signify for Biotech Investors - Kavout | AI
Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh - TradingView
Amgen Continues To Perform (NASDAQ:AMGN) - Seeking Alpha
Amgen Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Enterprise value to EBIT forward of Amgen Inc. – MUN:AMG - TradingView
Enterprise value to EBIT forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen consensus steady ahead of next earnings, shares tracked against big pharma peers - Ad-hoc-news.de
Enterprise value to EBIT forward of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGDB - TradingView
Amgen Inc. Actuals & Estimates (NASDAQ:AMGN) - TradingView
EU regulator backs revoking Amgen's right to sell rare-disease drug - Reuters
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked - WSJ
European Regulator Calls for Amgen's Tavneos to Have Authorization Revoked - marketscreener.com
EMA recommends revoking marketing authorisation for Amgen’s rare-disease drug - WKZO
Amgen faces EU withdrawal of rare-disorder therapy Tavneos - Seeking Alpha
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential - Insider Monkey
Amgen highlights obesity pipeline progress, shares track pharma peers - Ad-hoc-news.de
Meyer Handelman Co. Trims Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Actuals & Estimates (BX:AMG) - TradingView
Amgen clears key resistance level, shares range between support and new highs - Ad-hoc-news.de
Price to earnings forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen Inc. $AMGN is Aaron Wealth Advisors LLC's 5th Largest Position - MarketBeat
Enterprise value to revenue forward of Amgen Inc. – NASDAQ:AMGN - TradingView
Amgen reports new biosimilar data, shares in focus among healthcare peers - Ad-hoc-news.de
Amgen Inc. Actuals & Estimates (BMV:AMGN) - TradingView
Inside FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
Amgen’s Stock Is Down 10% From Its Highs: The $10 Billion Obesity Drug Bet That Could Define the Next Decade - TIKR.com
Amgen raises lower end of 2026 EPS target, shares stay in focus on NASDAQ - Ad-hoc-news.de
Amgen clears new 2026 high, shares extend biotech sector gains - Ad-hoc-news.de
Amgen dividend confirmed and capital plan detailed, shares under steady Wall Street scrutiny - Ad-hoc-news.de
AMGN Faces Market Scrutiny Over Data Integrity Issues - GuruFocus
Kestra Private Wealth Services LLC Grows Position in Amgen Inc. $AMGN - MarketBeat
Inside the FDA’s Effort to Pull an Amgen Drug Over Alleged Data Manipulation - Bloomberg.com
94,708 Shares in Amgen Inc. $AMGN Purchased by OP Asset Management Ltd - MarketBeat
Assenagon Asset Management S.A. Purchases 181,580 Shares of Amgen Inc. $AMGN - MarketBeat
Banque Cantonale Vaudoise Lowers Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. Stock 12‑Month Price Target Cut to $350.22 - TradingView
Willful Patent Verdict and Possible Treble Damages Could Be A Game Changer For Amgen (AMGN) - simplywall.st
IgG4-RD: From Diagnostic Delays to Collective Action in Rare Disease Care - Amgen
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):